# A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis

> **NCT00679744** · PHASE1 · WITHDRAWN · sponsor: **Exsar Corporation**

## Conditions studied

- G(M2) Ganglioside
- Tay-Sachs Disease Ganglioside
- Sandhoff Disease Ganglioside

## Interventions

- **DRUG:** Pyrimethamine

## Key facts

- **NCT ID:** NCT00679744
- **Lead sponsor:** Exsar Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-05
- **Primary completion:** 2010-03
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to lack of funding
- **Last updated:** 2013-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679744, "A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00679744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*